This site is intended for UK healthcare professionals

 
Sponsorship statement:
Funding for this educational activity has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found below:
  • Sponsored by Pfizer Limited. Pfizer has had no involvement or influence over the content of this educational material.
  • This activity has been funded by Bayer plc. through a reactive sponsorship. Bayer plc. had no involvement with the development of this material.
Pfizer_Logo_Color_CMYK
Logo_Bayer

Amyloidosis overview – prevalence, pathophysiology and treatment approaches

24 October 2025
Available for 1 CPD point(s)

Masterclass

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Amyloidosis is rapidly gaining recognition as a previously under-diagnosed cause of cardiomyopathy and heart failure. Here, experts from the National Amyloidosis Centre – the only centre in the UK specialising in the management of the condition – provide an overview of its prevalence, symptoms and key treatment principles.
Learning objectives
  • To understand the aetiology and key features of the most common forms of amyloidosis
  • To recognise the symptoms and signs that should prompt consideration of amyloidosis as a cause of cardiovascular symptoms
Speakers:

Professor Marianna Fontana Deputy Clinical and Research Lead
Dr Yousuf Razvi Clinical Research Fellow
Dr Dorota Rowczenio Head of Genetic Service
Angelique Smit Lead Clinical and Research Nurse
Professor Ashu Wechalekar Laboratory Director and Consultant Haematologist
Dr Carol Whelan Consultant Cardiologist

Categories

Tags

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.